Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 12/20 | 0.57 |
| ▸ | MET | P08581 | 6/20 | 0.46 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29509090 | 1.00 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL30122684 | 0.82 | RPS6KA5 (0.43) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| Quinoline SCHEMBL28070398 | 0.77 | ALDH1A1 (0.59) | RPS6KA5 | |
| SCHEMBL13378058 | 0.76 | RPS6KA5 (0.59) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL1446137 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL1472997 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL3222371 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL27987760 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL12011230 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL10197264 | 0.74 | RPS6KA5 (0.57) | RPS6KA5METRPS6KA4CDC7CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | claimed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | claimed |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| WO-2024077391-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIVERSITE DE MONTREAL (CA) | 2024-04-18 | — | — | WO | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4272832-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230348852-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | NOVARTIS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230348852-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | NOVARTIS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| EP-3705478-B1 | TRIAZINE COMPOUND AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SHENZHEN FORWARD PHARMACEUTICALS CO LTD (CN) | 2023-10-04 | — | — | EP | disclosed |
| US-20080096878-A1 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headaches; 2-(5-Bromo-1'1'-dioxido-2-oxo-2',3',5',6'-tetrahydrospiro[indole-3,4'-thiopyran]-1 (2H)-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide for example; use with other drugs | MERCK SHARP & DOHME LLC | 2008-04-24 | — | — | US | disclosed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007022501-A2 | USEFUL INDOLE COMPOUNDS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1680424-A2 | HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS | Neurogen Corporation (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005023806-A2 | HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | RPS6KA5 263/4885MET 1688/4885RPS6KA4 162/4885 |
| US-20230348852-A1 | METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY | B2M, EPAS1, LATS2 | RPS6KA5 4091/4885MET 523/4885RPS6KA4 4490/4885 |
| US-20080096878-A1 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headaches; 2-(5-Bromo-1'1'-dioxido-2-oxo-2',3',5',6'-tetrahydrospiro[indole-3,4'-thiopyran]-1 (2H)-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide for example; use with other drugs | CALCB, BDKRB2, BDKRB1 | RPS6KA5 1965/4885MET 3663/4885RPS6KA4 2898/4885 |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, BRAF, KRAS | RPS6KA5 314/4885MET 2662/4885RPS6KA4 348/4885 |
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | RPS6KA5 1727/4885MET 4860/4885RPS6KA4 2047/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | RPS6KA5 187/4885MET 2281/4885RPS6KA4 245/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | RPS6KA5 187/4885MET 2281/4885RPS6KA4 245/4885 |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, DPYD | RPS6KA5 441/4885MET 3192/4885RPS6KA4 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.